Mumbai: Just call the Omicron effect.
Medicine Azurnal antibiotics catapulted to become the best-selling pharmaceutical brand in January for the first time, overtaking the leader of the anti-diabetes therapy market, Mixard Human.
Antibiotics prescribed extensively during the third wave jumped 20 notches, seeing 100% growth in January to December to clean RS 73 Crore sales in the organized pharmaceutical retail market.
In addition, the Azurnal & Azee antibiotic brand, Painrelief Pills Calpol and Dolo, and Griltince cough syrup, each posted massive growth in 200% in January, together with the increase in Covid Caseload.
Antibiotics such as azithromycin, painkillers, anti-infection and cough syrup are the most prescribed treatment during omicron waves, with cases increasing exponentially during January, experts told TOI.
Usually, the order of power over in the domestic pharmaceutical retail market has been dominated by drugs for lifestyle diseases such as diabetes including human mixtures (novo nordisk), glycomet-gp (USV) and lanch (sanofi).
Azithral, marketed by Alembic Pharmaceuticals, profitable sales of Rs 450 Crore and the 14th highest sales brand ranking for the full year ending December 2021 (IMS org).
It has crossed the RS 250 Crore in sales in accordance with IMS IMS in terms of total moving (MAT) for December 2019.
Azurnral is the old brand, and enjoys the first driving advantage on the market.
It has been a market leader for years, and during Covid recorded large sales, an industrial player told TII.
Overall as therapy, anti-infection posted the highest growth in January, followed by breathing.
Also, other drugs arose during the third wave of seeing a surge in sales too.
Betadine, an antiseptic commonly used, is also sold as a solution to gargle for sore throat, up two ratings to secure the 8th position.
Omicron Helps Azurnic Antibiotics Beat Top Selling Anti-Diabetes Medication
